神经炎症
疾病
帕金森病
医学
神经科学
萧条(经济学)
心理学
内科学
宏观经济学
经济
作者
Laís Soares Rodrigues,Juliane Fagotti,Adriano Targa,Ana Carolina D. Noseda,Jéssica L. Ilkiw,Ana Paula Chuproski,Flávia W. C. Dorieux,Patricia D. dos Santos,Marcelo M. S. Lima
标识
DOI:10.1097/fbp.0000000000000512
摘要
Parkinson's disease (PD) is a neurodegenerative disorder classically associated with motor symptoms, but several nonmotor disturbances appear decades before the clinical diagnosis of the disease. A variety of hypotheses exist to explain the onset of PD, and neuroinflammation is one of the most investigated processes. In fact, strong evidence suggests that PD begins with an inflammatory process; currently, however, no anti-inflammatory therapy is clinically employed to alleviate the typical motor and the prodromal disturbances such as olfactory loss, cognitive impairments, depression and anxiety, sleep disturbances, and autonomic disorders. In fact, the classical dopaminergic therapies are not effective in alleviating these symptoms and there is no other specific therapy for these outcomes. Therefore, in this review, we will discuss novel potential pharmacological therapeutic strategies focusing on cannabinoids, caffeine, melatonin, and dietary compounds, which could act as adjuvants to regular PD therapy. These described chemicals have been extensively investigated as anti-inflammatory agents possibly promoting beneficial effects on nonmotor symptoms of PD. The investigation of the inflammatory process at different stages of PD progression should give us a better view of the therapeutic scenario and could improve our understanding of the mechanisms of this disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI